The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.
George Somlo
No relevant relationships to disclose
Joseph A. Sparano
No relevant relationships to disclose
Tessa Cigler
No relevant relationships to disclose
Gini F. Fleming
No relevant relationships to disclose
Thehang H. Luu
Research Funding - Bayer/Onyx; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Pfizer
Arti Hurria
Consultant or Advisory Role - Amgen; Genentech; GTx
Research Funding - Abraxis BioScience; Celgene; GlaxoSmithKline
Joanne E. Mortimer
Consultant or Advisory Role - Pfizer
Research Funding - Cephalon
Paul Henry Frankel
No relevant relationships to disclose
Helen K. Chew
No relevant relationships to disclose
Rita Nanda
No relevant relationships to disclose
Cynthia X. Ma
No relevant relationships to disclose
Alice P. Chen
No relevant relationships to disclose
Agustin Garcia
No relevant relationships to disclose
Linda T. Vahdat
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai; ImClone Systems
Honoraria - Bristol-Myers Squibb; Eisai
Research Funding - Bristol-Myers Squibb; Celldex; ImClone Systems; Novartis
David R. Gandara
Consultant or Advisory Role - Abbott Molecular
Jeffrey N. Weitzel
Research Funding - NCI